Frequent and serious adverse events reported during treatment period
Event . | Grade 1 . | Grade 2 . | Grades 3-4 . | Total, % . |
---|---|---|---|---|
Allergic reaction* | 5 | 5 | 0 | 50 |
Injection site reaction† | 6 | 3 | 0 | 45 |
Upper respiratory‡ | 7 | 1 | 0 | 40 |
Headache | 6 | 2 | 0 | 40 |
Fatigue | 2 | 4 | 0 | 30 |
Pneumonia | 0 | 0 | 2 | 10 |
Confusion | 0 | 0 | 1 | 5 |
Back pain | 0 | 0 | 1 | 5 |
Sepsis | 0 | 0 | 1 | 5 |
Event . | Grade 1 . | Grade 2 . | Grades 3-4 . | Total, % . |
---|---|---|---|---|
Allergic reaction* | 5 | 5 | 0 | 50 |
Injection site reaction† | 6 | 3 | 0 | 45 |
Upper respiratory‡ | 7 | 1 | 0 | 40 |
Headache | 6 | 2 | 0 | 40 |
Fatigue | 2 | 4 | 0 | 30 |
Pneumonia | 0 | 0 | 2 | 10 |
Confusion | 0 | 0 | 1 | 5 |
Back pain | 0 | 0 | 1 | 5 |
Sepsis | 0 | 0 | 1 | 5 |